MAP2K1 and hypertensive disorder: Furthermore, trametinib and other MKK1/2 inhibitors promote hypertension in up to 26% of patients, irrespective of whether patients are treated with the MKK1/2 inhibitors alone or in combination with a BRAF inhibitor [25], suggesting that dabrafenib does not mitigate the hypertensive effects of trametinib.